PMID- 35790253
OWN - NLM
STAT- MEDLINE
DCOM- 20220706
LR  - 20220706
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 42
IP  - 7
DP  - 2022 Jul
TI  - Real-world Experience With Pembrolizumab for Advanced-stage Head and Neck Cancer 
      Patients: A Retrospective, Multicenter Study.
PG  - 3653-3664
LID - 10.21873/anticanres.15854 [doi]
AB  - BACKGROUND/AIM: This study investigated the effectiveness of pembrolizumab with 
      or without chemotherapy on advanced-stage head and neck cancer (HNC), including 
      nasopharyngeal, sinonasal cavity and external auditory canal cancer, in a 
      real-world setting. PATIENTS AND METHODS: We retrospectively collected data from 
      97 HNC patients who were treated with pembrolizumab alone (n=60) or with 
      chemotherapy (n=37), and we investigated the association between 
      clinicopathological findings and treatment response or prognosis. RESULTS: 
      Patients treated with pembrolizumab and chemotherapy had a 1-year overall 
      survival (OS) of 72.8%, objective response rate (ORR) of 48.6%, and serious (>/=G3) 
      adverse events (AEs) of 29.7%. Patients treated with pembrolizumab alone had a 
      1-year OS of 51.9%, ORR of 21.7%, and >/=G3 AEs of 6.7%. Both the ORR and disease 
      control rate (DCR) in the pembrolizumab with chemotherapy group were 
      significantly better than those in the pembrolizumab group (p=0.074 and 
      p=0.00101, respectively). Among patients with distant metastasis, patients on 
      pembrolizumab with chemotherapy achieved significantly better OS than 
      pembrolizumab alone (p=0.0039). Among patients in the pembrolizumab group, both 
      AE-positive and better performance status were associated with longer OS (p=0.011 
      and p=0.0037, respectively). CONCLUSION: Our real-world experience reinforces the 
      durability and effectiveness of pembrolizumab for HNC patients. Additionally, our 
      results suggest that pembrolizumab with chemotherapy might be recommended for 
      patients with distant metastasis and no prior treatment. Further studies are 
      needed to determine the optimal treatment strategy for HNC.
CI  - Copyright (c) 2022 International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Nakano, Takafumi
AU  - Nakano T
AD  - Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
AD  - Department of Head and Neck Surgery, National Kyushu Cancer Center, Fukuoka, 
      Japan.
FAU - Yasumatsu, Ryuji
AU  - Yasumatsu R
AD  - Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan; yasumatsu.ryuji.847@m.kyushu-u.ac.jp.
FAU - Hashimoto, Kazuki
AU  - Hashimoto K
AD  - Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
FAU - Kuga, Ryosuke
AU  - Kuga R
AD  - Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
FAU - Hongo, Takahiro
AU  - Hongo T
AD  - Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
FAU - Yamamoto, Hidetaka
AU  - Yamamoto H
AD  - Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
FAU - Matsuo, Mioko
AU  - Matsuo M
AD  - Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
FAU - Wakasaki, Takahiro
AU  - Wakasaki T
AD  - Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
FAU - Jiromaru, Rina
AU  - Jiromaru R
AD  - Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
FAU - Manako, Tomomi
AU  - Manako T
AD  - Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
FAU - Toh, Satoshi
AU  - Toh S
AD  - Department of Head and Neck Surgery, National Kyushu Cancer Center, Fukuoka, 
      Japan.
FAU - Masuda, Muneyuki
AU  - Masuda M
AD  - Department of Head and Neck Surgery, National Kyushu Cancer Center, Fukuoka, 
      Japan.
FAU - Yamauchi, Moriyasu
AU  - Yamauchi M
AD  - Department of Otolaryngology - Head & Neck Surgery, Saga University Faculty of 
      Medicine, Saga, Japan.
FAU - Kuratomi, Yuichiro
AU  - Kuratomi Y
AD  - Department of Otolaryngology - Head & Neck Surgery, Saga University Faculty of 
      Medicine, Saga, Japan.
FAU - Taura, Masahiko
AU  - Taura M
AD  - Department of Otolaryngology Fukuoka University School of Medicine, Fukuoka, 
      Japan.
FAU - Takeuchi, Toranoshin
AU  - Takeuchi T
AD  - Department of Otorhinolaryngology, Kitakyushu Municipal Medical Center, 
      Kitakyushu, Japan.
FAU - Nakagawa, Takashi
AU  - Nakagawa T
AD  - Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - DPT0O3T46P (pembrolizumab)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized
MH  - *Antineoplastic Agents, Immunological/adverse effects
MH  - *Head and Neck Neoplasms/drug therapy
MH  - Humans
MH  - *Lung Neoplasms/pathology
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Pembrolizumab
OT  - head and neck cancer
OT  - immune checkpoint inhibitor
EDAT- 2022/07/06 06:00
MHDA- 2022/07/07 06:00
CRDT- 2022/07/05 20:41
PHST- 2022/04/29 00:00 [received]
PHST- 2022/05/20 00:00 [revised]
PHST- 2022/05/24 00:00 [accepted]
PHST- 2022/07/05 20:41 [entrez]
PHST- 2022/07/06 06:00 [pubmed]
PHST- 2022/07/07 06:00 [medline]
AID - 42/7/3653 [pii]
AID - 10.21873/anticanres.15854 [doi]
PST - ppublish
SO  - Anticancer Res. 2022 Jul;42(7):3653-3664. doi: 10.21873/anticanres.15854.